Healthcare company Ro stated on Wednesday that it will administer the Moderna COVID-19 vaccinations to eligible New Yorkers directly in their homes to help the elderly, disabled and the homebound facing logistical challenges accessing vaccination sites under the COVID-19 Vaccine Drive and in consultation with the New York State's Department of Health.
The company's free COVID-19 Vaccine Drive will be launched this week in select zip codes in Yonkers, New York, initially focusing on seniors 65 years old and older. In-home vaccination appointments can be scheduled at covidvaccinedrive.com by eligible individuals. The second doses for each recipient will be scheduled on site after the first shot and administered in-home as part of the programme. Vaccine recipients can use the hotline for general counselling regarding the vaccine and any potential side effects.
To ensure the COVID-19 Vaccine Drive reaches those with limited digital access or literacy challenges, the partners are working with Yonkers Mayor Mike Spano and Yonkers Office for the Aging to engage relatives and caregivers who can sign up eligible vaccine recipients and help coordinate in-home vaccinations on their behalf. Uber is donating free rides to help cover a portion of the transportation costs.
Upon the initial launch, the company will expand its COVID-19 Vaccine Drive in New York to additional communities. This programme is has received financial support from Firstmark, General Catalyst, TQ Ventures, BoxGroup, 3L Capital, Initialized Capital and Ramp.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients